Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-center Safety Observation of Zifivax in Large Population
NCT05890521Phase 4Unknown
- Sponsor
- Zhifei Biological
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ZF2001 in coronavirus disease 2019 (COVID-19), sponsored by Zhifei Biological. Primary endpoints: Serious Adverse Events at 1 year, Adverse Events at 1 year and 1 more. Status: unknown.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05890521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890521.